Johnson & Johnson’s coronavirus vaccine could resume with restrictions on who can receive it and warnings about its adverse effects.
The FDA and Centers for Disease Control and Prevention (CDC) recommended last week a temporary halt of Johnson & Johnson’s single-dose vaccine after six women reported rare blood-clotting disorders, out of millions who have received it.
Sunday, April 18, South Africa’s health regulator recommended that the government lift the pause on administering J&J’s COVID-19 vaccines, given that certain conditions are met.
“These conditions include, but are not limited to, strengthened screening and monitoring of participants who are at high risk of a blood clotting disorder,” the South African Health Products Regulatory Authority (SAHPRA) said.
“In addition, measures are to be implemented to ensure the safe management of any participants who develop vaccine-induced thrombosis and thrombocytopenia (VITT),” the statement added.